Aim:Given the encouraging results of the p53-Mdm2 inhibitor RG7388 in clinical trials and the vital function of miR-16-5p in suppressing cell proliferation,the aim of the present study was to investigate the combined ...Aim:Given the encouraging results of the p53-Mdm2 inhibitor RG7388 in clinical trials and the vital function of miR-16-5p in suppressing cell proliferation,the aim of the present study was to investigate the combined impact of RG7388 and miR-16-5p overexpression on the childhood acute lymphoblastic leukemia(chALL).Methods:miRTarBase and miRDB,along with KEGG and STRING databases,were used to predict miR-16-5p target genes and explore protein-protein interaction networks,respectively.B-and T-lymphoblastic cell lines,in addition to patient primary cells,were treated with RG7388.Ectopic overexpression of miR-16-5p in Nalm6 cell line was induced through cell electroporation and transfection of microRNA mimics was confirmed by qRT-PCR.Cell viability was evaluated using the MTT assay.Western blot analyses were performed to evaluate the effects of RG7388 and miR-16-5p upregulation on the protein levels of p53 and its downstream target genes in chALL cells.Paired sample t-test was employed for statistical analyses.Results:MTT assay showed RG7388-induced cytotoxicity in wild-type p53 Nalm6 cell line and p53 functional patient primary cells.However,CCRF-CEM and p53 non-functional leukemic cells indicated drug resistance.Western blot analyses validated the bioinformatics results,confirming the downregulation of WIP1,p53 stabilization,as well as overexpression of p21WAF1 and Mdm2 proteins in Nalm6 cells transfected with miR-16-5p.Moreover,enhanced sensitivity to RG7388 was observed in the transfected cells.Conclusion:This is the first study indicating the mechanistic importance of miR-16-5p overexpression in chALL and its inhibitory role in leukemia treatment when combined with the p53-Mdm2 antagonist,RG7388.These findings might be useful for researchers and clinicians to pave the way for better management of chALL.展开更多
基金This work was supported by the University of Isfahan(96/100000/4000).
文摘Aim:Given the encouraging results of the p53-Mdm2 inhibitor RG7388 in clinical trials and the vital function of miR-16-5p in suppressing cell proliferation,the aim of the present study was to investigate the combined impact of RG7388 and miR-16-5p overexpression on the childhood acute lymphoblastic leukemia(chALL).Methods:miRTarBase and miRDB,along with KEGG and STRING databases,were used to predict miR-16-5p target genes and explore protein-protein interaction networks,respectively.B-and T-lymphoblastic cell lines,in addition to patient primary cells,were treated with RG7388.Ectopic overexpression of miR-16-5p in Nalm6 cell line was induced through cell electroporation and transfection of microRNA mimics was confirmed by qRT-PCR.Cell viability was evaluated using the MTT assay.Western blot analyses were performed to evaluate the effects of RG7388 and miR-16-5p upregulation on the protein levels of p53 and its downstream target genes in chALL cells.Paired sample t-test was employed for statistical analyses.Results:MTT assay showed RG7388-induced cytotoxicity in wild-type p53 Nalm6 cell line and p53 functional patient primary cells.However,CCRF-CEM and p53 non-functional leukemic cells indicated drug resistance.Western blot analyses validated the bioinformatics results,confirming the downregulation of WIP1,p53 stabilization,as well as overexpression of p21WAF1 and Mdm2 proteins in Nalm6 cells transfected with miR-16-5p.Moreover,enhanced sensitivity to RG7388 was observed in the transfected cells.Conclusion:This is the first study indicating the mechanistic importance of miR-16-5p overexpression in chALL and its inhibitory role in leukemia treatment when combined with the p53-Mdm2 antagonist,RG7388.These findings might be useful for researchers and clinicians to pave the way for better management of chALL.
